Treatment of an Indolent T‐Cell Lymphoma of the Gastrointestinal Tract Harboring <i>STAT3::JAK2</i> With Jakafi (Ruxolitinib) With Significant Clinical Improvements

Authors

Institutions

Publication Details

Journal
eJHaem
Published
2025-05-08
DOI
https://doi.org/10.1002/jha2.70047
Citations
1
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
1.47
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Treatment of an Indolent T‐Cell Lymphoma of the Gastrointestinal Tract Harboring STAT3::JAK2 With Jakafi (Ruxolitinib) With Significant Clinical Improvements

H.-Y. Wang, Carolyn Mulroney, Xi Cao
1 citations
eJHaem
Lymphoma Diagnosis and Treatment
1.47
article

Treatment of an Indolent T‐Cell Lymphoma of the Gastrointestinal Tract Harboring STAT3::JAK2 With Jakafi (Ruxolitinib) With Significant Clinical Improvements

H.-Y. Wang, Carolyn Mulroney, Xi Cao
article en
1 citations

Abstract

No abstract available for this paper.
eJHaemVol. 6(3)
University of California San Diego (US)
Good health and well-being
Openalex Percentile: Top 20%
Lymphoma Diagnosis and Treatment
1.47
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Treatment of an Indolent T‐Cell Lymphoma of the Gastrointestinal Tract Harboring <i>STAT3::JAK2</i> With Jakafi (Ruxolitinib) With Significant Clinical Improvements — H.-Y. Wang, Carolyn Mulroney, et al. · eJHaem (2025) | TGRS Research Map | TGRS